Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857104 | 0.99 | CTSL (0.53) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL15584548 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL30500926 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL25393509 | 0.85 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL16590476 | 0.82 | FKBP1A (0.60) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL4870701 | 0.82 | LMNA (0.54) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL10152341 | 0.82 | CTSL (0.51) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL4861409 | 0.81 | CTSL (0.53) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL3647693 | 0.81 | CTSL (0.53) | LMNASMN1; SMN2HTTCTSLCTSB | |
| SCHEMBL25568627 | 0.81 | LMNA (0.60) | LMNASMN1; SMN2HTTALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094962-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20180221378-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180201617-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013163239-A1 | SYNTHESIS OF LACTAMS | TAVARES FRANCIS XAVIER (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | LMNA 2472/4885SMN1; SMN2 1629/4885HTT 4278/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | LMNA 2987/4885SMN1; SMN2 751/4885HTT 746/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | LMNA 1553/4885SMN1; SMN2 2179/4885HTT 1229/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | LMNA 2729/4885SMN1; SMN2 2529/4885HTT 1022/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | LMNA 2472/4885SMN1; SMN2 1629/4885HTT 4278/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | LMNA 2259/4885SMN1; SMN2 2678/4885HTT 2025/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | LMNA 2472/4885SMN1; SMN2 1629/4885HTT 4278/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | LMNA 2987/4885SMN1; SMN2 751/4885HTT 746/4885 |
| US-20180221378-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | LMNA 2729/4885SMN1; SMN2 2529/4885HTT 1022/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | LMNA 2729/4885SMN1; SMN2 2529/4885HTT 1022/4885 |
| US-20180201617-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | LMNA 2472/4885SMN1; SMN2 1629/4885HTT 4278/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | LMNA 2472/4885SMN1; SMN2 1629/4885HTT 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.